Biotest, Abbott deal

AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) exercised its opt-out right under a 2011 deal and Biotest will regain worldwide rights to tregalizumab. Biotest said it will not incur costs under the terminati...